Gliklazid

(Preusmjereno sa stranice BOVGTQGAOIONJV-UHFFFAOYSA-N)

Gliklazid je organsko jedinjenje, koje sadrži 15 atoma ugljenika i ima molekulsku masu od 323,411 Da.[5][6][7]

Gliklazid
Klinički podaci
Robne marke Diamicron, Diamicron MR, Glimicron, Mylan-Gliclazide
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 21187-98-4
ATC kod A10BB09
PubChem[1][2] 3475
DrugBank DB01120
ChemSpider[3] 3356
ChEBI CHEBI:31654 DaY
ChEMBL[4] CHEMBL427216 DaY
Hemijski podaci
Formula C15H21N3O3S 
Mol. masa 323,411
SMILES eMolekuli & PubHem
Fizički podaci
Tačka topljenja 181 °C (358 °F)
Farmakokinetički podaci
Poluvreme eliminacije 10,4 h
Izlučivanje Renalno (60-70%)
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Oralno

Osobine

uredi
Osobina Vrednost
Broj akceptora vodonika 4
Broj donora vodonika 2
Broj rotacionih veza 3
Particioni koeficijent[8] (ALogP) 1,9
Rastvorljivost[9] (logS, log(mol/L)) -3,2
Polarna površina[10] (PSA, Å2) 86,9

Reference

uredi
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. Karmoker, J.R.; Priya, R.J.; Sarkar, S.; Islam, S. (2017). „Comparative in vitro equivalence evaluation of some local Gliclazide brands of Bangladesh”. The Pharma Innovation Journal 6: 152-157. Pristupljeno 2017-08-15. 
  6. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.  edit
  7. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.  edit
  8. Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o. 
  9. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573.  edit
  10. Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286.  edit

Literatura

uredi

Spoljašnje veze

uredi